Evidence map›Paper›PMID 28498568›Full record

Trial reportClinical and experimental immunology2017

Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.

F G Karnell, D Lin, S Motley, T Duhen, N Lim, D J Campbell, L A Turka, H T Maecker, K M Harris

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Sustained immunotolerance in multiple sclerosis after stem cell transplant.Annals of clinical and translational neurology · 2022
    Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

F G KarnellImmune Tolerance Network, Bethesda, MD, USA.
D LinInstitute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
S MotleyBenaroya Research Institute, Seattle, WA, USA.
T DuhenBenaroya Research Institute, Seattle, WA, USA.
N LimImmune Tolerance Network, Bethesda, MD, USA.
D J CampbellBenaroya Research Institute, Seattle, WA, USA.
L A TurkaImmune Tolerance Network, Bethesda, MD, USA.
H T MaeckerInstitute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
K M HarrisImmune Tolerance Network, Bethesda, MD, USA.ORCID 0000-0002-6957-514X

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

Multiple sclerosis is an inflammatory T cell-mediated autoimmune disease. In a Phase II clinical trial, high-dose immunosuppressive therapy combined with autologous CD34

Indexed as

Hematopoietic Stem Cell TransplantationAdultB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesFemaleHumansKiller Cells, NaturalLymphocyte CountMaleMiddle AgedMultiple SclerosisTh17 CellsTh1 CellsTime FactorsCytokinesCyTOF mass cytometryflow cytometryimmune cell reconstitutionmultiple sclerosisT cells

Identifiers

PMID28498568
PMCPMC5543487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.